Bölüm notları
Former a16z investor Robin Guo explains how LionBio is developing nasal delivery platforms to bypass the blood-brain barrier for GLP-1s and neuropeptides. He discusses how frontier AI models are accelerating target discovery, why traditional pharma timelines are artificially slow, and how preventative neurotherapeutics could reshape diseases like Alzheimer’s over the next decade. Check out our sponsor Lovable: https://lovable.dev. Turn ideas into software people love.
MTS is a live news and interview show covering technology, business, politics, and culture as it happens.
Follow MTS:
X |…
Web sitesi: podcasters.spotify.com

